Clinician and Patient Evaluation of Improvement for Eyebrow and Eyelashes Hair Loss During Baricitinib Phase 3 Trials BRAVE-AA1 and BRAVE-AA2

The document presents the results of two phase 3 trials, BRAVE-AA1 and BRAVE-AA2, involving 654 and 546 patients respectively, testing the efficacy of baricitinib, a Janus kinase (JAK)1/JAK2 inhibitor, for severe alopecia areata (AA). The trials used both clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) scales to measure improvement in eyebrow (EB) and eyelash (EL) hair loss. Results showed that by Week 36, a significant proportion of patients on baricitinib (4 mg and 2 mg) showed improvements in EB and EL hair regrowth compared to those on placebo. For instance, in BRAVE-AA1, 31.4% and 32.1% of patients on 4 mg baricitinib achieved 0-1 scores for ClinRO and PRO respectively for eyebrows, compared to 3.2% and 3.1% on placebo. Similar results were observed in BRAVE-AA2. The study concludes that baricitinib demonstrated efficacy in EB and EL hair regrowth, with response rates being similar between ClinRO and PRO measures and consistent across trials.